Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
about
New developments in the management of severe skin and deep skin structure infections - focus on tedizolidAntibiotics in the clinical pipeline at the end of 2015.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Tedizolid phosphate.Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionA highly sensitive and efficient UPLC-MS/MS assay for rapid analysis of tedizolid (a novel oxazolidinone antibiotic) in plasma sample.Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.Tedizolid for treatment of acute bacterial skin and skin structure infections.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsPharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats.Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments.Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.Thrombocytopenia with Tedizolid and Linezolid.Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers.Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.
P2860
Q28083116-7E906FF3-2E1F-4CB5-B918-F002005E74C3Q30249262-B81EB4AD-E6BC-4DDA-BCB1-9475D6247BB0Q33438834-E2777180-2995-4362-BD98-D6016D3F97D0Q34612944-EB7093E7-5102-4F21-9688-EEE6C3A2557CQ34922189-7137E8E7-93F8-4C24-B0F2-B189F1CA336FQ35997199-72B92344-8A46-4852-AE46-3B0457D77574Q36327804-CC02AFD5-23AD-4F91-B351-A2CB54C63F70Q38347869-33B9623B-B268-45A8-9B80-994741513C45Q38352171-B5DE35CF-21A9-4E11-B4F3-B3CCAE4A5EC5Q38536296-6E003167-E9F2-4FF9-A92A-8C0F509E2997Q38554583-CD73CE09-9E4F-41D1-AC5D-D7D629608B51Q38777085-93C0DA27-EF7F-45D1-9226-E4706B2A622FQ39067666-4848FD91-2E33-4BD8-A829-164D4B1D54D4Q40035130-DCB17FCE-EDE7-433C-868C-5F9C4D9B0BBDQ40267578-828EA967-4FF2-4847-90CE-9AE06377AAE6Q40675142-10C2F7D8-D956-4B12-AC76-2AF65604FC34Q47737103-D52A4A96-84DF-408E-991C-389E8544B80DQ50104909-EBAEE72A-C049-47F6-B218-423971A6E70DQ55511795-19AA4B3D-1576-4001-9F52-F51785C26106Q55547799-E6B5DDF5-A7B9-4E7B-A22A-D36D89809F55
P2860
Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Absorption, distribution, meta ...... l prodrug tedizolid phosphate.
@en
Absorption, distribution, meta ...... l prodrug tedizolid phosphate.
@nl
type
label
Absorption, distribution, meta ...... l prodrug tedizolid phosphate.
@en
Absorption, distribution, meta ...... l prodrug tedizolid phosphate.
@nl
prefLabel
Absorption, distribution, meta ...... l prodrug tedizolid phosphate.
@en
Absorption, distribution, meta ...... l prodrug tedizolid phosphate.
@nl
P2093
P356
P1476
Absorption, distribution, meta ...... l prodrug tedizolid phosphate.
@en
P2093
Edward Fang
Howard J Dreskin
Jeffrey B Locke
Kenneth Bartizal
Philippe Prokocimer
Shawn Flanagan
P304
P356
10.1124/DMD.113.056697
P577
2014-05-29T00:00:00Z